EFFECT OF IMMUNIZATION WITH INACTIVATED GP120-DEPLETED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) IMMUNOGEN ON HIV-1 IMMUNITY, VIRAL-DNA, AND PERCENTAGE OF CD4 CELLS
Rj. Trauger et al., EFFECT OF IMMUNIZATION WITH INACTIVATED GP120-DEPLETED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) IMMUNOGEN ON HIV-1 IMMUNITY, VIRAL-DNA, AND PERCENTAGE OF CD4 CELLS, The Journal of infectious diseases, 169(6), 1994, pp. 1256-1264
A 1-year study measured the effect of administration of an inactivated
human immunodeficiency virus type 1 (HIV-1) immunogen in incomplete F
reund's adjuvant (IFA) on HIV-1-specific immunity and viral burden in
asymptomatic HIV-1-infected patients. A total of 103 patients were enr
olled in this double-blind, randomized study comparing immunogen in ad
juvant with adjuvant alone. This study was conducted at nine medical c
enters throughout the United States. Significant differences in cell-m
ediated immune responses to HIV-1 and p24 core antigen were observed b
etween the treated and control groups (P <.01). Compared with controls
, treated patients as a group had a significantly lower rate of increa
se in viral DNA as determined by quantitative HIV-1 DNA-polymerase cha
in reaction (P =.016). Significant differences in the rate of percent
CD4 cell decline were also observed between the 2 groups (P =.024). Th
ese data suggest that augmentation of HIV-1-specific immunity via immu
notherapy may alter the rate of increase of HIV-1 DNA in peripheral bl
ood mononuclear cells and stabilize the percent of CD4 cell decline in
relatively healthy HIV-1-infected persons.